Cardiovascular Autonomic Neuropathy

Cardiac Autonomic Testing And Treating Heart Disease. “A Clinical Perspective” 2 Of 2

Articles /

Abstract Background Coronary heart disease (CHD) is a major health concern, affecting nearly half the middle-age population and responsible for nearly one-third of all deaths. Clinicians have several major responsibilities beyond diagnosing CHD, such as risk stratification of patients for major adverse cardiac events (MACE) and treating risks, as well as the patient. This second […]

Cardiac Autonomic Testing And Treating Heart Disease. “A Clinical Perspective” 2 Of 2 Read More »

Cardiac Autonomic Testing And Diagnosing Heart Disease. “A Clinical Perspective” 1 Of 2

Leave a Comment / Articles /

Abstract Background Coronary heart disease (CHD) is a major health concern, affecting nearly half the middle-age population and responsible for nearly one-third of all deaths. Clinicians have responsibilities beyond diagnosing CHD, including risk stratification of patients for major adverse cardiac events (MACE), modifying the risks and treating the patient. In this first of a two-part

Cardiac Autonomic Testing And Diagnosing Heart Disease. “A Clinical Perspective” 1 Of 2 Read More »

Differential Effects of Adrenergic Antagonists (Carvedilol vs. Metoprolol) on Parasympathetic and Sympathetic Activity: A Comparison of Measures 2 of 2

Leave a Comment / Articles /

BACKGROUND  Cardiovascular autonomic neuropathy (CAN) is recognized as a significant health risk, correlating with risk of heart disease, silent myocardial ischemia or sudden cardiac death. Beta-blockers are often prescribed to minimize risk.  OBJECTIVES  In this second of two articles, the effects on parasympathetic and sympathetic activity of the alpha/beta-adrenergic blocker, Carvedilol, are compared with those

Differential Effects of Adrenergic Antagonists (Carvedilol vs. Metoprolol) on Parasympathetic and Sympathetic Activity: A Comparison of Measures 2 of 2 Read More »

Ranolazine Improves Autonomic Balance In Heart Failure When Added To Guideline-Driven Therapy

Leave a Comment / Articles /

Background The effect of ranolazine (RAN) on cardiac autonomic balance in congestive heart failure (CHF) was studied. Methods Fifty-four CHF patients were randomized to (1) open-label RAN (RANCHF) added to usual therapy vs. (2) usual therapy (NORANCHF). Parasympathetic and sympathetic (P&S) measurements were taken at baseline and at 12 months. Results A total of 16/27

Ranolazine Improves Autonomic Balance In Heart Failure When Added To Guideline-Driven Therapy Read More »

Clinical Autonomic Dysfunction

Leave a Comment / Articles /

PART 1: Introduction and History of Autonomic Nervous System Monitoring CHAPTER 1: Introduction to Parasympathetic and Sympathetic Monitoring This introductory section starts with a review of the “Old School” information commonly taught in medical school, including the anatomy of the autonomic nervous system (ANS) and its two branches, the parasympathetic and sympathetic nervous systems; the

Clinical Autonomic Dysfunction Read More »

PAGES

FORMS

RESOURCES

Sign Up For Our Newsletter

Physio PS © 2024 All Rights Reserved. The material and information provided by Physio PS is for general information purposes only. You should not rely upon this material or information for basis of making healthcare, treatment, or diagnosis decisions. While Physio PS strives to provide the most correct and up-to-date information and data, Physio PS makes no representations or warranties of any kind, expressed or implied, about the completeness, accuracy, reliability, suitability, or availability with respect to the information, products, services, or related graphics contained. Any reliance placed on such material is therefore strictly at your own risk. Reporting Information is supplied under license by NCRC LLC. * ‘RFa’ is known to be a measure of Parasympathetic activity and ‘LFa’ is known to be a measure of Sympathetic activity, based on reference: Colombo J, Arora RR, DePace NL, Vinik AI, Clinical Autonomic Dysfunction: Measurement, Indications, Therapies, and Outcomes. Springer Science + Business Media, New York, NY; 2014.

Scroll to Top

Become An Authorized Distributor